Since 1993, the AACR has awarded more than $542 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.
Dr. Channing Der serves as the Sarah Graham Kenan Professor of Pharmacology at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill. Having received his PhD from the University of California at Irvine, Dr. Der went on to complete his postdoctoral research training at the Dana-Farber Cancer Institute and Harvard Medical School. As a two-time PanCAN-AACR grant recipient...
AACR has been the Scientific Partner of Stand Up To Cancer (SU2C) since 2008. It supports the scientific oversight, expert peer review and administration of many SU2C-funded grants. To keep the scientific community informed of the impact of this scientific partnership, a subset of research articles published by SU2C-funded scientists are summarized.
For Michael Jensen, MD, a grant from the AACR came at a good time. It was 1996, and Jensen was at the Fred Hutchinson Cancer Research Center in Seattle for his fellowship as a pediatric oncologist-hematologist, working in the laboratory of....
The AACR is committed to help mitigate the disproportionate burden of cancer on certain segments of the population. As a cornerstone of its educational and advocacy efforts, the AACR recently released the inaugural AACR Cancer Disparities Progress Report. A complementary strategy...
Dr. Sonia del Rincón and the Stand Up to Cancer (SU2C) Canada Metastatic Breast Cancer Dream Team are looking to understand the impact of MAP kinase–interacting serine/threonine kinases 1 and 2 (MNK1/2) inhibitors on metastatic breast cancer...
Pancreatic cancer is forecasted to become the 2nd deadliest cancer in the United States by 2030. The AACR, in partnership with the Lustgarten Foundation and Pancreatic Cancer Action Network (PanCAN), brought together top scientists in the AACR Special Conference...
AACR grantee Sergey Karakashev, PhD, and colleagues at the Wistar Institute have recently shown that the efficacy of PARP inhibitors can be extended to HR-proficient epithelial ovarian cancers using a combinatorial approach with inhibitors of the histone-modifying enzyme EZH2.